MiniMed Group (NASDAQ:MMED) Stock Rating Upgraded by Zacks Research

Key Points

• Zacks Research upgraded MiniMed Group (NASDAQ:MMED) to a "hold" rating in a recent research note.
• Multiple firms initiated coverage with ratings from "neutral" to "overweight"/"buy"; the consensus is a "Moderate Buy" with a consensus price target of $22.45.
• Shares opened at $13.92 and have a 12‑month range of $12.80–$20.48; MiniMed is a global medtech company that commercializes all parts of an integrated diabetes management system.

MiniMed Group (NASDAQ:MMED - Get Free Report) was upgraded by analysts at Zacks Research to a "hold" rating in a research note issued on Thursday,Zacks.com reports.

Other analysts have also issued reports about the stock. Piper Sandler started coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a "neutral" rating and a $16.00 target price for the company. Deutsche Bank Aktiengesellschaft started coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a "buy" rating and a $20.00 target price for the company. Wells Fargo & Company started coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set an "overweight" rating and a $26.00 target price for the company. Barclays started coverage on shares of MiniMed Group in a research report on Wednesday, April 1st. They set an "overweight" rating and a $26.00 target price for the company. Finally, BTIG Research started coverage on shares of MiniMed Group in a research report on Tuesday, March 31st. They set a "buy" rating and a $25.00 target price for the company. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $22.45.

MiniMed Group Stock Performance

Shares of NASDAQ MMED opened at $13.92 on Thursday. MiniMed Group has a 12-month low of $12.80 and a 12-month high of $20.48.

MiniMed Group Company Profile

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes. Today, we are the only player in the market that commercializes all parts of an integrated diabetes management system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.